These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3584344)

  • 21. Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
    Suzuki Y; Sasamoto Y; Yoshijima C; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Pharm Biomed Anal; 2020 May; 184():113202. PubMed ID: 32114159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.
    Niwa T; Yazawa T; Kodama T; Uehara Y; Maeda K; Yamada K
    Nephron; 1990; 56(3):241-5. PubMed ID: 2077405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma concentrations of anionic uremic toxins in hemodialysis patients and their effects on protein binding of pravastatin].
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2015; 135(6):821-8. PubMed ID: 26028417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excretion of the uraemic metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human urine.
    McTigue JJ; Henderson SJ; Lindup WE
    Nephron; 1990; 55(2):214-5. PubMed ID: 2362637
    [No Abstract]   [Full Text] [Related]  

  • 26. Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant.
    Costigan MG; Yaqoob M; Lindup WE
    Nephrol Dial Transplant; 1996 May; 11(5):803-7. PubMed ID: 8671898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma.
    Huang Y; Sun H; Frassetto L; Benet LZ; Lin ET
    Rapid Commun Mass Spectrom; 2006; 20(10):1611-4. PubMed ID: 16628600
    [No Abstract]   [Full Text] [Related]  

  • 28. Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin.
    Henderson SJ; Lindup WE
    Biochem Pharmacol; 1990 Dec; 40(11):2543-8. PubMed ID: 2268372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and physicochemical properties of the furan dicarboxylic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia.
    Costigan MG; Gilchrist TL; Lindup WE
    J Pharm Pharmacol; 1996 Jun; 48(6):635-40. PubMed ID: 8832500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 43(2):110-6. PubMed ID: 3086761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hippuric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in serum and urine. Analytical approaches and clinical relevance in kidney diseases.
    Liebich HM; Bubeck JI; Pickert A; Wahl G; Scheiter A
    J Chromatogr; 1990 Feb; 500():615-27. PubMed ID: 2329153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?
    Costigan MG; Callaghan CA; Lindup WE
    Nephron; 1996; 73(2):169-73. PubMed ID: 8773339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations between Plasma Levels of Anionic Uremic Toxins and Clinical Parameters in Hemodialysis Patients.
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2016; 136(8):1177-84. PubMed ID: 27477735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients.
    De Smet R; Vogeleere P; Van Kaer J; Lameire N; Vanholder R
    J Chromatogr A; 1999 Jun; 847(1-2):141-53. PubMed ID: 10431358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia.
    Costigan MG; Lindup WE
    Kidney Int; 1996 Mar; 49(3):634-8. PubMed ID: 8648903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid.
    Costigan MG; Yaqoob M; Lindup WE
    Nephrol Dial Transplant; 1995; 10(5):648-52. PubMed ID: 7566577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?
    Luce M; Bouchara A; Pastural M; Granjon S; Szelag JC; Laville M; Arkouche W; Fouque D; Soulage CO; Koppe L
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of uremic toxins and nonesterified fatty acids on drug and thyroid hormone binding in serum.
    Lim CF; Stockigt JR
    Clin Chem; 1998 Nov; 44(11):2380-1. PubMed ID: 9799777
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
    Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
    Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.